ストックスクリーナーアプリを入手
452.33
0.41%
-1.85
アフターアワーズ：
451.00
-1.33
-0.29%
前日終値:
$454.18
開ける：
$452.01
24時間の取引高:
641.00K
Relative Volume:
0.61
時価総額：
$59.29B
収益：
$2.46B
当期純損益:
$-319.09M
株価収益率:
-183.13
EPS:
-2.47
ネットキャッシュフロー:
$-52.09M
1週間 パフォーマンス:
-3.26%
1か月 パフォーマンス:
+39.27%
6か月 パフォーマンス:
+83.32%
1年 パフォーマンス:
+61.14%
1日の値動き範囲:
$451.12
$457.29
1週間の範囲:
$442.38
$469.81
52週間の値動き範囲:
$205.87
$469.81
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
452.33 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.05 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
579.61 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
704.07 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
297.96 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
How sentiment analysis helps forecast Alnylam Pharmaceuticals Inc.Quarterly Trade Summary & Daily Entry Point Alerts - Newser
Sentiment analysis tools applied to Alnylam Pharmaceuticals Inc.2025 Retail Activity & Safe Entry Point Alerts - Newser
Technical analysis overview for Alnylam Pharmaceuticals Inc. stock2025 Risk Factors & Consistent Growth Equity Picks - Newser
Using Python tools to backtest Alnylam Pharmaceuticals Inc. strategiesLong Setup & Weekly Watchlist of Top Performers - Newser
Using Bollinger Bands to evaluate Alnylam Pharmaceuticals Inc.Market Growth Report & Safe Capital Growth Tips - Newser
Visual analytics tools that track Alnylam Pharmaceuticals Inc. performance2025 Sector Review & Fast Exit Strategy with Risk Control - Newser
Using RSI to spot recovery in Alnylam Pharmaceuticals Inc.2025 Technical Overview & Smart Investment Allocation Tips - Newser
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? - Yahoo Finance
Next Generation Drug Conjugates Market Report 2025-2035, with Profiles of Advanced Accelerator Applications, Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Geron, & Ionis Pharmaceuticals - Yahoo Finance
Applying big data sentiment scoring on Alnylam Pharmaceuticals Inc.July 2025 Pullbacks & High Accuracy Investment Signals - Newser
Leading vs lagging indicators on Alnylam Pharmaceuticals Inc. performanceMarket Performance Report & Advanced Technical Signal Analysis - Newser
What MACD and RSI say about Alnylam Pharmaceuticals Inc.July 2025 Selloffs & Reliable Trade Execution Plans - Newser
Will breakout in Alnylam Pharmaceuticals Inc. lead to full recovery2025 Price Action Summary & Low Risk Entry Point Tips - Newser
How institutional ownership impacts Alnylam Pharmaceuticals Inc. stockDividend Hike & Free High Return Stock Watch Alerts - Newser
Real time breakdown of Alnylam Pharmaceuticals Inc. stock performanceBuy Signal & Expert Curated Trade Ideas - Newser
Backtesting results for Alnylam Pharmaceuticals Inc. trading strategiesJuly 2025 Closing Moves & Safe Entry Point Identification - Newser
What does recent volatility data suggest for Alnylam Pharmaceuticals Inc.CEO Change & Free AI Powered Buy and Sell Recommendations - Newser
How to build a custom watchlist for Alnylam Pharmaceuticals Inc.Market Rally & Weekly Market Pulse Updates - Newser
Published on: 2025-08-28 01:33:20 - Newser
Alnylam Pharmaceuticals Inc. stock volume spike explained2025 Trading Volume Trends & Fast Gain Stock Trading Tips - Newser
What’s the recovery path for long term holders of Alnylam Pharmaceuticals Inc.Trade Volume Report & Real-Time Buy Zone Alerts - Newser
Chart overlay techniques for tracking Alnylam Pharmaceuticals Inc.July 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
Best data tools to analyze Alnylam Pharmaceuticals Inc. stockEntry Point & Low Risk Entry Point Tips - Newser
What moving averages say about Alnylam Pharmaceuticals Inc.Day Trade & AI Enhanced Execution Alerts - Newser
Published on: 2025-08-27 13:49:28 - Newser
Alnylam’s ConTTRibute Study: A Closer Look at Real-World Impact on ATTR Amyloidosis - TipRanks
Alnylam’s ALN-APP Study: A Promising Step in Alzheimer’s Treatment - TipRanks
Alnylam’s Patisiran-LNP Study: Key Insights for Investors - TipRanks
Alnylam’s ALN-HTT02 Study: A Potential Game-Changer for Huntington’s Disease - TipRanks
Alnylam’s Innovative Approach in Liver Cancer Treatment: A Phase 1 Study Update - TipRanks
Earnings visualization tools for Alnylam Pharmaceuticals Inc.2025 Price Momentum & Community Driven Trade Alerts - Newser
Applying chart zones and confluence areas to Alnylam Pharmaceuticals Inc.2025 Institutional Moves & Fast Exit and Entry Trade Guides - Newser
Will Alnylam Pharmaceuticals Inc. outperform the marketJuly 2025 Patterns & Smart Swing Trading Techniques - Newser
What’s next for Alnylam Pharmaceuticals Inc. stock priceWeekly Trend Summary & Comprehensive Market Scan Insights - Newser
Leading RNAi Therapeutics Company Alnylam Set for Key September Healthcare Conference Circuit - Stock Titan
Measuring Alnylam Pharmaceuticals Inc.’s beta against major indicesLong Setup & Accurate Technical Buy Alerts - Newser
Can trapped investors hope for a rebound in Alnylam Pharmaceuticals Inc.July 2025 Intraday Action & Low Drawdown Investment Strategies - Newser
Reversal Traders Monitor Alnylam Pharmaceuticals Inc. for Entry getLinesFromResByArray error: size == 0 - newsyoung.net
Applying sector rotation models to Alnylam Pharmaceuticals Inc.CEO Change & Safe Capital Preservation Plans - Newser
Quantitative breakdown of Alnylam Pharmaceuticals Inc. recent moveBear Alert & Accurate Buy Signal Notifications - Newser
Market reaction to Alnylam Pharmaceuticals Inc.’s recent newsChart Signals & Community Trade Idea Sharing Platform - Newser
Can Alnylam Pharmaceuticals Inc. hit a new high this month2025 Valuation Update & High Conviction Buy Zone Alerts - Newser
Intraday pattern recognizer results for Alnylam Pharmaceuticals Inc.Trade Performance Summary & Comprehensive Market Scan Reports - Newser
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
Alnylam Pharmaceuticals Inc (ALNY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | EVP Chief R&D |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
21,676 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
29,466 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Aug 18 '25 |
Sale |
453.27 |
2,274 |
1,030,727 |
50,121 |
| Greenstreet Yvonne | Chief Executive Officer |
Aug 18 '25 |
Sale |
453.27 |
6,979 |
3,163,346 |
56,221 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Aug 18 '25 |
Sale |
453.27 |
1,396 |
632,759 |
22,719 |
| BONNEY MICHAEL W | Director |
Aug 18 '25 |
Option Exercise |
70.20 |
11,250 |
789,750 |
28,054 |
| BONNEY MICHAEL W | Director |
Aug 18 '25 |
Sale |
450.00 |
11,250 |
5,062,500 |
16,804 |
1.25%
0.33%
大文字化:
|
ボリューム (24 時間):